安进减肥药Maritide临床研究表现出平均减重20%效果

Core Insights - Amgen's weight loss drug Maritide demonstrated an average weight reduction of 20% in the first part of its Phase 2 clinical trial [1] Company Summary - Amgen is advancing its clinical research with Maritide, focusing on obesity treatment [1] Industry Summary - The obesity treatment market is seeing significant developments with new drug candidates like Maritide showing promising results in clinical trials [1]